Ospemifene use in postmenopausal women

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 839-849

  Gennari, Luigi ^a   Merlotti, Daniela ^a   Valleggi, Fabrizio ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Estrogen; Menopause; Ospemifene; Osteoporosis; SERM; Vaginal atrophy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLONIDINE; DROLOXIFENE; ESTRADIOL; ESTROGEN RECEPTOR; GABAPENTIN; OSPEMIFENE; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STRONTIUM RANELATE; TAMOXIFEN; TOREMIFENE; VITAMIN D;

ALZHEIMER DISEASE; BLOOD CLOTTING DISORDER; BONE; BREAST; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG METABOLISM; DRUG SYNTHESIS; DYSPAREUNIA; ENDOMETRIUM CANCER; ESOPHAGITIS; ESOPHAGUS ULCER; HORMONE RESPONSE; HOT FLUSH; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SKIN ATROPHY; STROKE; THROMBOEMBOLISM; URINARY TRACT INFECTION; UTERUS CANCER; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINITIS; VASOMOTOR DISORDER; VERTEBRA FRACTURE; VULVA ATROPHY; VULVA DISEASE;

ATROPHY; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VAGINA; VULVA;

EID: 67649595194     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902953715     Document Type: Review

References (63)

1. Lund KJ. Menopause and the menopausal transition. Med Clin North Am 2008;92(5):1253-1271
2. Nelson HD. Menopause. Lancet 2008;371(9614):760-770
3. Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res 1992;7:1005-1010
4. Riggs BL, Melton LJ 3rd. The prevention and treatment of osteoporosis. N Engl J Med 1992;327(9):620-627
5. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endo Rev 2002;23:279-302 (Pubitemid 34651948)
6. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38:S4-9 (Pubitemid 43190767)
7. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model of involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-773 (Pubitemid 28224192)
8. Patten RD, Karas RH. Estrogen replacement and cardiomyocyte protection. Trends Cardiovasc Med 2006;16(3):69-75
9. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006;12(5):483-497 (Pubitemid 44288706)
10. Gustafsson JA. Estrogen receptor beta: a new dimension in estrogen mechanism of action. J Endocrinol 1999;163(3):379-383
11. Bord S, Horner A, Beavan S, et al. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 2001;86(5):2309-2314 (Pubitemid 32472956)
12. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
13. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004
14. Practice Committee of American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2008;90(5 Suppl ):S88-102
15. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941
16. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
17. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477
18. Vassilopoulou-Sellin R. Breast cancer and hormonal replacement therapy. Ann NY Acad Sci 2003;997:341-350 (Pubitemid 38491089)
19. HRT: What are women (and their doctors) to do? [editorial]. Lancet 2004;364:2069-2070
20. Barlow DH. The medical management of menopause: to treat or not to treat? Ann NY Acad Sci 2008;1127:134-139
21. Jenkins MR, Sikon AL. Update on nonhormonal approaches to menopausal management. Cleve Clin J Med 2008;75(Suppl 4):S17-24
22. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-2018
23. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-818
24. Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Emerg Drugs 2001;6:137-154 (Pubitemid 32381381)
25. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 2005;96:15-25 • Interesting and up-to-date overview of the pharmacology of SERMs. (Pubitemid 40267682)
26. Gennari L, Merlotti D, De Paola V, Nuti R. Raloxifene in breast cancer prevention. Expert Opin Drug Saf 2008b;7:259-270 (Pubitemid 351802826)
27. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629 (Pubitemid 36210865)
28. Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-379
29. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647 • First clinical trial demonstrating the efficacy of a SERM, raloxifene, for the prevention and treatment of osteoporosis in postmenopausal women. (Pubitemid 27510100)
30. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-1754 (Pubitemid 28492005)
31. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645 (erratum JAMA. 1999;282:2124)
32. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Miner Metab 1996;14:1-9 (Pubitemid 126712731)
33. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-822
34. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-2202 (Pubitemid 32269244)
35. Morello KC, Wurz GT, DeGregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol 2002;43:63-76 (Pubitemid 34722788)
36. Gennari L. Ospemifene hormos. Curr Opin Investig Drugs 2004;5(4):448-455
37. Bachman GA, Komi J, Hanley RM. A New SERM, Ophena (Ospemifene), effectively treats vulvovaginal atrophy in postmenopausal women: Results from a Pivotal Phase 3 Study. The Endocrine Society's 90th Annual Meeting, San Francisco, June 15-18, 2008, P2-513
38. Willson TM, Norris JD, Wagner BL, et al. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 1997;138(9):3901-3911
39. Qiang Q, Zhengt H, Dahlund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol levels and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141(2):809-820
40. Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999;73(4):500-507 (Pubitemid 29256939)
41. Degregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000;56(6-7):469-475 •• Detailed analysis of the pharmacokinetic profile of ospemifene. (Pubitemid 30745881)
42. Wiebe VJ, Benz CC, Shemano I, et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 1990;25(4):247-251
43. Bryson S, Cornelissen K, Anttila M. Absorption, metabolism and excretion of (3H)-ospemifene following a single oral dose to postmenopausal women. Clin Pharmacol Ther 2005;77:82 [abstract]
44. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77(4-5):271-279
45. Kallio A, Guo T, Lamminen E, et al. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol 2008;289(1-2):38-48
46. Parikka V, Lehenkari P, Harkonen PL, et al. The effect of two selective estrogens raloxifene and FC1271a on osteoclast survival and resorption in vitro. Bone 1998;23:S5-S552
47. Michael H, Härkönen PL, Kangas L, et al. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007;151(3):384-395 (Pubitemid 46842673)
48. Hellmann-blumberg U, Taras TL, Wurz GT, et al. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat 2000;60(1):63-70
49. Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005;7(6):R881-9
50. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 2005;97(3):230-240 (Pubitemid 41607573)
51. Wurz GT, Hellmann-Blumberg U, DeGregorio MW. Pharmacologic effects of ospemifene in rhesus macaques: a pilot study. Basic Clin Pharmacol Toxicol 2008;102(6):552-558 (Pubitemid 351691963)
52. Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 2003;10(5):440-447
53. Rutanen EM, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003;10(5):433-439 • Phase II results indicating the efficacy of ospemifene for the treatment of vulvar and vaginal atrophy (second study).
54. Voipio SK, Komi J, Halonen K, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43(3):207-214 • Phase II results indicating the efficacy of ospemifene for the treatment of vulvar and vaginal atrophy (first study).
55. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24(4):314-318 (Pubitemid 43992675)
56. Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18(3):152-158
57. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005;12(2):202-209
58. Available from: http//www.clinical trials.gov; A service of the US National Institute of Health developed by the National Library of Medicine. Trial identifiers: NCT00566982 and NCT00729469
59. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91(19):1654-1662 (Pubitemid 29479933)
60. Morello K, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42(4):361-372 (Pubitemid 36433876)
61. Gennari L, Merlotti D, De Paola V, et al. Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag 2008;4(6):1-14
62. Taylor HS. Designing the ideal selective estrogen receptor modulator-an achievable goal? Menopause 2009 [Epub ahead of print]
63. NDA 22-242, Lasofoxifene Tartrate (Proposed trade name: FABLYN), Pfizer, Inc, Proposed Indication: 'FABLYN is a selective estrogen receptor modulator indicated for treatment of osteoporosis in postmenopausal women at increased risk of fracture'. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs (September 8, 2008); Prepared by Division of Reproductive and Urologic Products Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration August 15, 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-01-FDA.pdf. [Last accessed 4 March 2009]